{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:42:31Z","timestamp":1789684951971,"version":"4.0.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["21798"],"award-info":[{"award-number":["21798"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Heart failure is a common condition associated with significant mortality. <jats:italic>Objective<\/jats:italic>: to determine the prescription patterns of medications for the treatment of heart failure in a cohort of patients from Colombia.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective study based on the clinical records of patients diagnosed with heart failure between 2019 and 2020. Sociodemographic, clinical, paraclinical, and pharmacological variables and the specialty of the treating physician were identified. Patients were classified according to functional class, stage, and left ventricular ejection fraction (LVEF).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 4742 patients were evaluated, with a mean age of 68.2\u2009\u00b1\u200913.8 years and a male predominance (61.3%). A total of 92.0% were classified as stage C and 54.8% as functional class I, the mean LVEF was 42.9\u2009\u00b1\u200914.8%, and 32.53% had reduced LVEF. 30.7% did not have LVEF data. The most common causes were ischemic heart disease (44.0%) and arterial hypertension (29.7%). A total of 5.2% had hospitalizations for heart failure in the last year, and 75.6% were attended by a general practitioner. These patients were treated with \u03b2-blockers (88.3%), renin-angiotensin-aldosterone system inhibitors (RAASis) (83.1%), loop diuretics (46.8%), and mineralocorticoid receptor antagonists (MRAs) (46.5%). Triple therapy with RAASis\u2009+\u2009\u03b2-blockers+MRAs was received by 56.4% of patients with reduced LVEF, 32.8% with mildly reduced LVEF and19.5% with preserved LVEF, while quadruple therapy adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was given just to 4.6% with reduced LVEF.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The treatment that patients with heart failure with preserved LVEF is relatively simpler and is closer to the recommendations, while the proportion of indicated therapies according to guidelines is lower among those with reduced LVEF.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325515","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:48:48Z","timestamp":1750787328000},"page":"e0325515","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heart failure treatment patterns: A pharmacoepidemiological descriptive study in Colombia (The HEATCO study)"],"prefix":"10.1371","volume":"20","author":[{"given":"Manuel E.","family":"Machado-Duque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-7658","authenticated-orcid":true,"given":"Andr\u00e9s","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-0101","authenticated-orcid":true,"given":"Luis F.","family":"Valladales-Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7776-9270","authenticated-orcid":true,"given":"Juan","family":"Sebasti\u00e1n Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda de Rosario","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-7636","authenticated-orcid":true,"given":"David","family":"Vizcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":true,"given":"Jorge E.","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"17","key":"pone.0325515.ref001","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"G Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"4","key":"pone.0325515.ref002","article-title":"Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association","volume":"133","author":"Members Writing Group","year":"2016","journal-title":"Circulation"},{"key":"pone.0325515.ref003","first-page":"6","article-title":"Cap\u00edtulo 2. Introducci\u00f3n, epidemiolog\u00eda de la falla cardiaca e historia de las cl\u00ednicas de falla cardiaca en Colombia","author":"E G\u00f3mez","year":"2016","journal-title":"Rev Colomb Cardiol"},{"issue":"8","key":"pone.0325515.ref004","first-page":"628","article-title":"ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"CW Yancy","year":"2017","journal-title":"J Card Fail"},{"issue":"8","key":"pone.0325515.ref005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"JA Borovac","year":"2020","journal-title":"World J Cardiol"},{"issue":"4","key":"pone.0325515.ref006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.cjca.2020.12.028","article-title":"A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction","volume":"37","author":"RJH Miller","year":"2021","journal-title":"Can J Cardiol"},{"issue":"21","key":"pone.0325515.ref007","first-page":"376","article-title":"The Treatment of Heart Failure with Reduced Ejection Fraction","volume":"117","author":"D Berliner","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"10106","key":"pone.0325515.ref008","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"M Metra","year":"2017","journal-title":"Lancet"},{"key":"pone.0325515.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6018\/eglobal.13.4.178311","article-title":"Adherencia al tratamiento farmacol\u00f3gico y no farmacol\u00f3gico en pacientes con falla cardiaca","volume":"13","author":"LZ Rojas S\u00e1nchez","year":"2014","journal-title":"Enfermer\u00eda Global"},{"issue":"12","key":"pone.0325515.ref010","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: Visualization of Intersecting Sets","volume":"20","author":"A Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"6","key":"pone.0325515.ref011","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"J Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"pone.0325515.ref012","first-page":"334","article-title":"Registro colombiano de falla cardiaca (RECOLFACA): resultados","volume":"28","author":"JE G\u00f3mez-Mesa","year":"2021","journal-title":"Rev Colomb Cardiolog\u00eda"},{"issue":"5","key":"pone.0325515.ref013","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10557-020-07015-8","article-title":"Angiotensin Receptor Neprilysin Inhibitors-2019 Update","volume":"34","author":"G Chalikias","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"21","key":"pone.0325515.ref014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"JJV McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0325515.ref015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0325515.ref016","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00392-017-1138-6","article-title":"Treatment of chronic heart failure in Germany: a retrospective database study","volume":"106","author":"S St\u00f6rk","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"pone.0325515.ref017","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"H Dokainish","year":"2017","journal-title":"Lancet Glob Health"},{"key":"pone.0325515.ref018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijcard.2021.11.018","article-title":"Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure","volume":"349","author":"F Rea","year":"2022","journal-title":"Int J Cardiol"},{"issue":"1","key":"pone.0325515.ref019","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s40615-021-01202-5","article-title":"Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study","volume":"10","author":"L Mathews","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"issue":"3","key":"pone.0325515.ref020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/10547738221147402","article-title":"Experiences of Facilitators and Inhibitors to Treatment Adherence in Patients with Heart Failure","volume":"32","author":"SF Gheiasi","year":"2023","journal-title":"Clin Nurs Res"},{"issue":"19","key":"pone.0325515.ref021","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global Variations in Heart Failure Etiology, Management, and Outcomes","volume":"329","author":"G-CHF Investigators","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"pone.0325515.ref022","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/ehf2.12688","article-title":"Physical vs. multidimensional frailty in older adults with and without heart failure","volume":"7","author":"G Testa","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"11","key":"pone.0325515.ref023","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamacardio.2019.3511","article-title":"Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults","volume":"4","author":"H Kundi","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"2","key":"pone.0325515.ref024","article-title":"American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients","volume":"47","author":"JE G\u00f3mez\u2010Mesa","year":"2023","journal-title":"Clinical Cardiology"},{"issue":"17","key":"pone.0325515.ref025","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary","volume":"79","author":"PA Heidenreich","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0325515.ref026","first-page":"3","article-title":"Actualizaci\u00f3n 2022 del consenso colombiano de insuficiencia card\u00edaca con fracci\u00f3n de eyecci\u00f3n reducida: cap\u00edtulo de falla card\u00edaca, trasplante card\u00edaco e hipertensi\u00f3n pulmonar de la Asociaci\u00f3n Sociedad Colombiana de Cardiolog\u00eda y Cirug\u00eda Cardiovascular","volume":"29","author":"A Rivera-Toquica","year":"2022","journal-title":"Rev Colomb Cardiol"},{"issue":"17","key":"pone.0325515.ref027","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"SD Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0325515.ref028","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial","volume":"7","author":"PARAGON-HF Investigators","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"15","key":"pone.0325515.ref029","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0325515.ref030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"SD Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0325515.ref031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial","volume":"10","author":"SD Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"4","key":"pone.0325515.ref032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","article-title":"Comorbidities in heart failure with preserved ejection fraction","volume":"47","author":"A Deichl","year":"2022","journal-title":"Herz"},{"issue":"11","key":"pone.0325515.ref033","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jash.2015.08.011","article-title":"Effectiveness and clinical inertia in the management of hypertension in patients in Colombia","volume":"9","author":"ME Machado-Duque","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"10","key":"pone.0325515.ref034","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart Failure With Preserved Ejection Fraction","volume":"329","author":"MM Redfield","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"pone.0325515.ref035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes","volume":"146","author":"G Filippatos","year":"2022","journal-title":"Circulation"},{"key":"pone.0325515.ref036","doi-asserted-by":"crossref","first-page":"897423","DOI":"10.3389\/fcvm.2022.897423","article-title":"Efficacy and safety of sacubitril\/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"9","author":"W Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"pone.0325515.ref037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jcm12010099","article-title":"The Prescription Pattern of Heart Failure Medications in Reduced, Mildly Reduced, and Preserved Ejection Fractions","volume":"12","author":"T Rastogi","year":"2022","journal-title":"JCM"},{"issue":"10244","key":"pone.0325515.ref038","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"M Vaduganathan","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"pone.0325515.ref039","first-page":"313","article-title":"Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"73","author":"MG Crespo-Leiro","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"pone.0325515.ref040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry","volume":"22","author":"M Lain\u0161\u010dak","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"pone.0325515.ref041","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"AP Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"pone.0325515.ref042","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"M Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"pone.0325515.ref043","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"GMC Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"pone.0325515.ref044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2023.01.050","article-title":"Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction","volume":"193","author":"M Musse","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:48:57Z","timestamp":1750787337000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325515"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Curcio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325515","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}